Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/29600
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSTOCCO, Fernando G.-
dc.contributor.authorEVARISTO, Ederson-
dc.contributor.authorSILVA, Anderson C.-
dc.contributor.authorANTONIO, Victor Zandona de-
dc.contributor.authorPFEIFFER, Juergen-
dc.contributor.authorRANGACHARI, Narasimhan-
dc.contributor.authorBELARDINELLI, Luiz-
dc.contributor.authorVERRIER, Richard L.-
dc.date.accessioned2018-11-21T17:06:44Z-
dc.date.available2018-11-21T17:06:44Z-
dc.date.issued2018-
dc.identifier.citationJOURNAL OF CARDIOVASCULAR PHARMACOLOGY, v.72, n.3, p.129-135, 2018-
dc.identifier.issn0160-2446-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/29600-
dc.description.abstractWe compared the pharmacokinetic (PK) profile and electrocardiographic (ECG) changes in response to intratracheal instillation of flecainide acetate into the left atrium and ventricle with intravenous (IV) flecainide acetate administration. In 12 closed-chest anesthetized Yorkshire pigs, we monitored the QRS complex and PR, JT(c), and QT(c) intervals during sinus rhythm and correlated changes with venous plasma drug concentrations before and at 2, 5, 10, 15, and 30 minutes after drug administration. Intratracheal instillation of flecainide (0.75 and 1.5 mg/kg, rapid bolus) caused dose/concentration-dependent increases in the QRS complex duration of 10% and 19%, respectively, at 2 minutes, coinciding with peak venous plasma levels (1688 +/- 177 and 2808 +/- 217 ng/mL, respectively). IV infusion of flecainide (2 mg/kg) over 2 or 10 minutes similarly prolonged QRS complexes and PR intervals (both, P < 0.001). Intratracheal flecainide instillation increased PR interval briefly at 5 minutes. Neither intratracheal nor IV flecainide affected JT(c) or QT(c) intervals. Thus, the PK pattern of intratracheal instillation of flecainide is comparable to IV administration, although the absolute plasma concentrations were higher with IV infusion. Both modes of delivery elicited ECG changes that were consistent with the expected pharmacological activity of flecainide.-
dc.description.sponsorshipInCarda Therapeutics-
dc.language.isoeng-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.relation.ispartofJournal of Cardiovascular Pharmacology-
dc.rightsrestrictedAccess-
dc.subjectinhalation-
dc.subjectflecainide-
dc.subjectatrial fibrillation-
dc.subjectpharmacokinetics-
dc.subjectpulmonary delivery-
dc.subject.otherantiarrhythmic-drug therapy-
dc.subject.otheronset atrial-fibrillation-
dc.subject.otherthe-pocket approach-
dc.subject.othermanagement-
dc.titleComparative Pharmacokinetic and Electrocardiographic Effects of Intratracheal and Intravenous Administration of Flecainide in Anesthetized Pigs-
dc.typearticle-
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINS-
dc.identifier.doi10.1097/FJC.0000000000000605-
dc.identifier.pmid29923887
dc.subject.wosCardiac & Cardiovascular Systems-
dc.subject.wosPharmacology & Pharmacy-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalSILVA, Anderson C.:Univ Sao Paulo, Fac Med, Sao Paulo, Brazil; Beth Israel Deaconess Med Ctr, 99 Brookline Ave,RN-301, Boston, MA 02215 USA-
hcfmusp.author.externalPFEIFFER, Juergen:Sci Res Partners, San Francisco, CA USA-
hcfmusp.author.externalRANGACHARI, Narasimhan:InCarda Therapeut, Newark, CA USA-
hcfmusp.author.externalBELARDINELLI, Luiz:InCarda Therapeut, Newark, CA USA-
hcfmusp.author.externalVERRIER, Richard L.:Univ Sao Paulo, Fac Med, Sao Paulo, Brazil; Harvard Med Sch, Boston, MA USA-
hcfmusp.description.beginpage129-
hcfmusp.description.endpage135-
hcfmusp.description.issue3-
hcfmusp.description.volume72-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000446478900001-
hcfmusp.origem.id2-s2.0-85053014420-
hcfmusp.publisher.cityPHILADELPHIA-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAlboni P, 2004, NEW ENGL J MED, V351, P2384, DOI 10.1056/NEJMoa041233-
hcfmusp.relation.referenceAlboni P, 2010, HEART, V96, P546, DOI 10.1136/hrt.2009.187963-
hcfmusp.relation.referenceAliot E, 2011, EUROPACE, V13, P161, DOI 10.1093/europace/euq382-
hcfmusp.relation.referenceAndrade JG, 2018, HEART RHYTHM, V15, P9, DOI 10.1016/j.hrthm.2017.10.002-
hcfmusp.relation.referenceBELARDINELLI L, 2017, CIRCULATION S1, V136-
hcfmusp.relation.referenceBelardinelli L, 2013, J PHARMACOL EXP THER, V344, P23, DOI 10.1124/jpet.112.198887-
hcfmusp.relation.referenceBoriani G, 2004, DRUGS, V64, P2741, DOI 10.2165/00003495-200464240-00003-
hcfmusp.relation.referenceColilla S, 2013, AM J CARDIOL, V112, P1142, DOI 10.1016/j.amjcard.2013.05.063-
hcfmusp.relation.referenceHELLESTRAND KJ, 1982, BRIT HEART J, V48, P140-
hcfmusp.relation.referenceMurdock DK, 2010, J ATR FIBRILLATION, V2, P705-
hcfmusp.relation.referencePiccini JP, 2016, LANCET, V388, P829, DOI 10.1016/S0140-6736(16)31277-6-
hcfmusp.relation.referenceSardar MR, 2016, HEART FAIL CLIN, V12, P205, DOI 10.1016/j.hfc.2015.08.017-
hcfmusp.relation.referenceTJANDRAMAGA TB, 1986, BRIT J CLIN PHARMACO, V22, P309, DOI 10.1111/j.1365-2125.1986.tb02892.x-
hcfmusp.relation.referenceZimetbaum P, 2012, CIRCULATION, V125, P381, DOI 10.1161/CIRCULATIONAHA.111.019927-
dc.description.indexMEDLINE-
dc.identifier.eissn1533-4023-
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2022-06-16-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros


Files in This Item:
File Description SizeFormat 
art_STOCCO_Comparative_Pharmacokinetic_and_Electrocardiographic_Effects_of_Intratracheal_and_2018.PDF
  Restricted Access
476.77 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.